. In the current study, the biologic activity of plasma membrane-anchored heregulin was evaluated in human breast cells. Transmembrane heregulin binds to cells expressing p180 , induces p185 HER-2/neu phosphorylation, and increases DNA synthesis in cells overexpressing the HER-2/neu gene product. In addition, when cells containing heregulin receptors are co-cultured with heregulin-producing cells, specific in vivo associations are observed. This study demonstrates that transmembrane heregulin is functionally active and suggest it is capable of playing a role in cell-cell communication and subsequent signal transduction in vivo.
Several polypeptide growth factors interact with specific receptors on target cells via autocrine or paracrine mechanisms (1) . Cleavage of transmembrane growth factor precursors to yield soluble mature forms is a rather common mechanism of protein activation (reviewed in Ref. 2) . However, proteolytic processing of growth factor precursors does not always convert them from inactive to active forms, but can instead serve to transform fully active membrane-associated ligands into soluble forms. Transmembrane precursors of epidermal growth factor receptor (HER-1) 1 ligands, including EGF (3), TGF-␣ (4, 5), boss (6) , as well as non-EGF-like ligands such as colonystimulating factor 1 (CSF-1), Kit ligand (KL), and TNF-␣ (2) are capable of binding target receptors on the membranes of adjacent cells, activating specific cellular functions. (1) . This indicates that a third mechanism of growth factor activity, termed a juxtacrine interaction (7), may play a relevant role in intercellular communication.
A family of growth factors with homology to EGF was initially identified based on their ability to stimulate phosphorylation of p185 HER-2/neu (8) . The heregulins (HRGs), also known as neu differentiation factor (NDF; Ref. 9) , and their neurotropic homologs acetylcholine receptor-inducing activity (ARIA; Ref. 10) , glial growth factors (11) , and sensory and motorderived growth factor (SMDF; Ref. 12) are all alternatively spliced variants of a single gene. Two additional HRG genes called neuregulin-2 (13, 14) and neuregulin-3 (15) have also been cloned. The heregulins or neuregulins are involved in complex interactions with all four type I receptor tyrosine kinase (RTK I) family members, i.e. HER-1, HER-2, HER-3, and HER-4 (16 -18) . Heregulin binds directly to p180 HER-3 and p180 homodimers at low affinity, inducing only p180 autophosphorylation (19 -21) . HER-2/HER-4 and HER-2/ HER-3 receptor heterodimers can also bind HRG, with the later constituting a high affinity receptor for the ligand (22, 23) .
A variety of studies have demonstrated that HER-2/neu receptor is the critical signaling partner in heregulin-induced RTK I signal transduction (16, 24, 25) . Analysis of the amino acid sequence predicted by the HRG splice variants ␣ and ␤ 1-2 cDNAs, suggests that they are synthesized as large membrane-bound precursors. Recent data indicate that this is the case for the neuronal homologues of HRG ARIA (26) , and SMDF (27) , as well as for NDF produced by cultured neonatal Schwann cells (28) . Cleavage of pro-ARIA and pro-NDF, from NDF-transfected COS-7, as well as Chinese hamster ovary cells, yields the soluble mature forms of these molecules. These are homologs to the 45-kDa species originally identified in the conditioned media from MDA-MB-231 cells (29, 30) . These membrane-bound growth factor precursors raise the possibility that juxtacrine mechanisms may also exist for the HRGs and may play an important role in interacting with their respective receptors.
Overexpression of HER-2 receptor tyrosine kinase is found in 25-30% of breast and ovarian cancers and is correlated with poor prognosis in patients whose tumors contain this alteration (31, 32) . Elucidation of the mechanisms by which the HER-2 receptor increases tumor growth after activation via both receptor overexpression and/or HRG-induced phosphorylation (33, 34) is potentially important in understanding the putative pathogenic role of HER-2 in human malignancies. In this study, results are presented showing that membrane-bound heregulin can be detected on the surface of MDA-MB-231 human breast cancer cells and that this form of the molecule can establish contact with HER-2/neu-expressing cells. These in-teractions can be specifically blocked by soluble 7-kDa rHRG, full-length rHRG, or anti-HER-2 antibodies. Plasma membranes isolated from HRG-producing MDA-MB-231 cells are  capable of activating p185 HER-2/neu in both HER-2/neu-nonoverexpressing and HER-2/neu-overexpressing human breast cell lines. These data demonstrate that transmembrane heregulin produced by human breast cancer cells is a functional ligand and suggest that it may be capable of activating receptors in neighboring cells via a juxtacrine mechanism.
EXPERIMENTAL PROCEDURES
Cells-Cells were routinely grown in 1ϫ RPMI (Life Technologies, Inc.), containing 10% heat-inactivated fetal bovine serum (FBS), penicillin G (100,000 units/liter), and streptomycin sulfate (100 mg/liter). Adenocarcinona breast cell lines MDA-MB-231, MDA-MB-468, MCF-7, and SK-BR-3 were obtained from the American Type Culture Collection (ATCC). The HER-2/neu-overexpressing cell line MCF-7 RV/H2 and the mock control cells MDA-MB-231C were obtained by retroviral infection of MCF-7, and MDA-MB-231 cells as described previously (33, 34) .
Immunofluorescence-Cell lines were harvested using 1ϫ Versene (Life Technologies, Inc.), counted under the microscope by trypan blue exclusion, and plated on glass slides by centrifugation at 500 rpm for 10 min (Cytospin 2, Shandon). Specific staining for both p185 HER-2/neu and HRG was performed using the anti-p185
HER-2/neu polyclonal antibody R60 (32) or two anti-HRG antibodies (sheep polyclonal 17753-76A and hamster monoclonal 3B4, Genentech), respectively. Final color for HRG detection was developed with an alkaline phosphatase detection system following the manufacturer's instructions (Vectastain ABC-AP, Vector). Fluorescein avidin DCS (Vector) was applied for detection of p185 HER-2/neu by immunofluorescence. Observation of cell staining and pictures were done in a Zeiss Axiophot microscope.
Immunohistochemistry-Treatments, as described in the legend for Fig. 7 , were performed by pre-incubation of the cells 15 min at 37°C as indicated. Cells were plated onto chamber slides (LabTek, NalgeNunc) using 1% FBS supplemented RPMI medium and incubated at 37°C for 2 days. After that time period the medium was removed and the slides rinsed twice with PBS. The cells were fixed in cold acetone and a double immunohistochemistry procedure performed using the Vector AB system. The same antibodies described in the immunofluorescence section were used for detection of HER-2 receptor and membrane-bound heregulin. The alkaline phosphatase (pink substrate) and peroxidase (brown) systems were used for color development as directed by the manufacturer (Vector). Cell observation and photomicrography were done with an Olympus BH2 microscope.
Plasma Membrane Isolation-Plasma membranes were isolated using standard cell fractionation techniques as described (35) . In brief, 10 6 to 10 8 cells were harvested from subconfluent cultures using a 1ϫ solution of Versene (Life Technologies, Inc.), containing protease inhibitors as follows: 2 mM phenylmethylsulfonyl fluoride, 0.2 mg/ml trypsin inhibitor, 0.15 units/ml aprotinin, 1 mg/ml pepstatin A, 10 mM bestatin, 1 mM N-ethylmaleimide, 20 mM leupeptin, and 1 mM EDTA. Cells were pelleted at 1,000 ϫ g for 10 min, resuspended in 5 ml of buffer A (10 nM Tris, pH 7.4, plus 250 mM sucrose and a mixture of protease inhibitors as above), and then washed twice using the same procedure. The cell pellet was resuspended in buffer A in a 1:10 w/v ratio and homogenized (Dounce homogenizer) until a 80 -90% cell rupture was observed under the inverted microscope (Diaphot, Nikon). Centrifugation of the cell homogenate (H) at 1,000 ϫ g for 10 min yielded the pellet (P1). The resultant supernatant (S1) from this centrifugation was then spun at 15,000 ϫ g for 50 min to obtain the pellet (P2) and supernatant (S2). Microsomes (M) were pelleted by spinning S2 at 105,000 ϫ g for 1 h; the supernatant of this last centrifugation consists of cell cytoplasm (Cyt). Plasma membranes (PM) were purified from the microsomal fraction using a self-generating density gradient made of 17% Percoll (Amersham Pharmacia Biotech) in 25 ml of buffer A. For this, the microsomal fraction was resuspended in Percoll and centrifuged at 35,000 ϫ g for 50 min. A tube containing density marker beads was run in parallel to monitor density banding. The PM fraction was collected at a typical density of 1.04 -1.045 mg/ml. Membranes were further purified by loading the PM fraction on top of a 50% sucrose step cushion. After centrifugation at 105,000 ϫ g for 1 h, plasma membranes were collected at the interphase and resuspended in 12 ml of water for a further centrifugation at 105,000 ϫ g for 60 min. Purified PM were then obtained as a thin layer on top of the Percoll pellet and resuspended in 0.2-0.4 ml of water for their storage at Ϫ80°C. All the steps were performed at 4°C under sterile conditions. Enzyme Activities-Marker enzymes were used for assessment of PM purity and possible cross-contamination. The activity of the next set of enzymes was quantitated: (a) Na ϩ ,K ϩ -ATPase as a PM marker (36) , (b) succinate-cytochrome c reductase as a marker for the inner mitochondrial membrane (37) , (c) glucose-6-phosphatase to detect possible endoplasmic reticulum contamination (37, 38) , and (d) acid phosphatase for lysosomes (38) . The total protein concentration in each fraction was determined by the BCA protein assay (Pierce) as indicated by the manufacturer. Specific activities were calculated as micromoles of product/min ϫ mg of protein.
Stimulation of p185 HER-2/neu Phosphorylation-MCF-7 cells (1.0 ϫ 10 5 ) were seeded in each well of a 24-well plate and allowed to grow for 4 days (to ϳ90% confluence) in 50% Dulbecco's modified Eagle's medium, 50% Ham's F-12 medium containing 10% FBS. The cells were serum-starved for 1.5 h prior to stimulation with either recombinant heregulin or MDA-MB-231 plasma membranes. A p185 HER-2/neu phosphorylation dose-response curve was generated by treating the cells with the indicated concentrations of rHRG-␤1-(177-244) for 8 min at room temperature. Cells were also treated in parallel with dilutions of the MDA-MB-231 PM suspension. All sample dilutions were made in medium containing 0.1% BSA. Following stimulation, the supernatants were removed and phosphorylation was stopped by adding 100 l of SDS sample buffer to each well. Tyrosine-phosphorylated proteins were detected by Western blot using an anti-phosphotyrosine horseradish peroxidase conjugate (Transduction Laboratories) and a chemiluminescent substrate (Amersham Pharmacia Biotech). Specific p185 phosphorylation was quantitated by densitometry. Data were analyzed using a non-linear least squares regression algorithm (39) .
Western Blot-MDA-MB-231 and MCF-7 RV/H2 samples (20 g/ lane) obtained from the cell fractionation procedure were mixed in a 1:1 ratio with SDS sample buffer, boiled for 5 min, and run in a 8% Tris-glycine gel (Novex). The protein concentration of the lysates was determined using a BCA protein assay (Pierce). A Western blot of the gel was probed using the anti-HRG-␣ C-20 antibody (Santa Cruz Biotechnology). Following incubation with the secondary antibody, consisting of a streptavidin-horseradish peroxidase conjugate (Calbiochem), the blot was visualized with a chemiluminescent substrate (Amersham Pharmacia Biotech).
Immunoprecipitation of p185 HER-2/neu
-Blocking of the activation of HER-2/neu tyrosine kinase activity by transmembrane-HRG in the plasma membrane of MDA-MB-231 cells was examined by Western blot analysis. HER-2/neu-overexpressing breast cell lines SK-BR-3, MCF-7 RV/H2, and MCF-7 parentals were cultured in six-well plates using 1ϫ RPMI medium (10% FBS). Subconfluent cultures were serum-starved for 2 h before treatment as indicated in Fig. 5 . The anti-receptor antibodies were added to the cells before treatment with either form of the ligand. Pre-incubation with the antibodies was allowed for 30 min at room temperature prior to treatment. Anti-HRG antibodies were preincubated with the ligand or PM solutions. After incubation at room temperature with either form of HRG for approximately 8 min, cells were washed once with a 20 mM glycine, 150 mM NaCl, pH 2.5, buffer, followed by two washes with cold PBS, after which 0.2 ml of lysis buffer (radioimmune precipitation buffer) were immediately added. Cell lysis was allowed for 10 min on ice, and cells were scraped from the wells using a rubber policeman. Lysates were cleared by centrifugation and kept at Ϫ80°C. Lysates (200 mg of total protein) were incubated overnight at 4°C with either 3 l of the anti-p185 HER-2/neu polyclonal antibody R60 (32) or 5 mg of the anti-p185 HER-2/neu monoclonal antibody 3E8 (Genentech). Immunoprecipitation was achieved by addition of 30 l of a Protein A-AffiGel conjugate (Bio-Rad), followed by incubation for another 1 h at 4°C. Immunoprecipitated proteins were pelleted by brief centrifugation, washed extensively with lysis buffer, and processed for electrophoresis and Western blot analysis.
Binding Assays-MCF-7 cells were seeded (1.0 ϫ 10 5) in each well of a 24-well plate and grown to ϳ80% confluence in 50% Dulbecco's modified Eagle's medium, 50% Ham's F-12 medium containing 10% FBS. The cells were washed briefly with ice-cold medium containing 0.1% BSA and placed on ice. All subsequent steps were performed at 0 -4°C. A competitive displacement curve for HRG binding was generated by incubating the MCF-7 cells with 50 ϫ 10 3 cpm 125 I-labeled rHRG-␤1-(177-244) (specific activity 213 mCi/pmol), in the presence of the indicated concentrations of unlabeled rHRG-␤1-(177-244). Binding was also performed on samples containing 0.36 and 0.90 mg/ml MDA-MB-231 PM suspension or 0.087 and 0.17 mg/ml MCF-7H2 PM suspension.
After incubating for about 16 h, the cells were washed extensively with ice-cold medium containing 0.1% BSA. Cell-associated counts were then removed with 0.1 N NaOH, 1.0% SDS at room temperature. Binding data was analyzed using a non-linear regression algorithm (39) . 3 H]thymidine incorporation assay. In brief, 5 ϫ 10 3 cells were plated in multiscreen HATF 96-well plates (Millipore) using RPMI medium containing 1% FBS. After 24 h at 37°C in a 5% CO 2 atmosphere, cells were treated as indicated and reincubated for 2 more days under the same conditions, after which received a 2-Ci pulse of [ 3 H]thymidine in 20 l of culture medium. Thymidine incorporation was stopped after 4 h of incubation by filtration and washing of the wells twice with PBS. DNA was precipitated with ice-cold 5% trichloroacetic acid, and the [ 3 H]thymidine incorporated by the cells was measured in a scintillation counter.
RESULTS

Transmembrane Heregulin Is Bound to the Plasma Membrane of MDA-MB-231
Cells-Heregulin precursors on the plasma membranes of the HRG-producing cell line MDA-MB-231 were identified using immunocytochemical techniques ( Fig. 1) . When MDA-MB-231 cells were incubated with either polyclonal (Fig. 1 ) or monoclonal (data not shown) anti-HRG antibodies, intense membrane-associated staining on the surface was observed (Fig. 1, bottom right panel) . The HRG-positive staining (red fluorescence) surrounded the nuclei (counterstained in blue), always associated with plasma membranes, and possibly also with the cytoplasm (Fig. 1, bottom right) . MCF-7 RV/H2 cells, which do not produce heregulin (34) , were processed in parallel and demonstrated no membrane-related HRG staining, despite their high levels of HER-2 expression. The results obtained by performing immunocytochemistry with the anti-HRG antibodies on both the MDA-MB-231 cells, and the MCF-7 RV/H2 cells confirmed previous analyses by both reverse transcriptase-polymerase chain reaction (Taqman) as well as Northern blot of HRG expression in these two cell lines (8, 34) , consistent with the presence of membrane-associated HRG precursors on the plasma membrane of MDA-MB-231 cancer cells and its absence from the plasma membranes of the MCF-7 breast cancer cells. An anti-p185 HER-2/neu antibody was used to assess the patterns and intensities of HER-2/neu receptor expression on these same two cell lines (Fig. 1, upper  panels) . Strong plasma membrane fluorescence was seen in the MCF-7 cells, transfected to overexpress HER-2/neu, indicating positive staining for the receptor (upper left panel). Conversely, there was little or no fluorescence on the plasma membranes of the single-copy, low HER-2/neu-expressing MDA-MB-231 cells (upper right panel). Given their significantly different relative expression levels of HRG and HER-2, these two cell lines were used to conduct further biochemical and biologic analyses related to HER-2 activation by membrane-associated HRG.
Purification of Plasma Membranes-In order to characterize the membrane-bound HRG precursors, PM fractions of the two cell lines were prepared. Purified plasma membrane fractions from both MDA-MB-231 cells and MCF-7 RV/H2 cells were obtained using conventional biochemical techniques (35) , and assessed by examination with a transmission electron microscope (data not shown).
Possible cross-contamination of PM fractions with membrane vesicles from intracellular organelles was further investigated by measuring the activity of classical marker enzymes for lysosomes (acid phosphatase) (38) , mitochondria (succinatecytochrome c reductase) (37) , and cytoplasm (glucose-6-phosphatase) (38) . The PM fraction shows enrichment on the specific activity of the Na ϩ /K ϩ ATPase (36), a marker associated with plasma membrane, with no evidence of significant crosscontamination (Table I) .
Evidence of the presence of HRG precursors on the PMs from MDA-MB-231 cells, but not from MCF-7 RV/H2 cells, was seen in Western blot analysis of fractions resulting from the cell fractionation procedure (Fig. 2) . The homogenate, lysosomal/ mitochondrial, and microsomal fractions contained two predominant bands (with molecular masses of 105 and 65 kDa), recognized by a HRG-␣-specific antibody, raised against the C terminus of the molecule (Fig. 2, lanes 1-3) . Comparison of the molecular size of these forms and the molecular mass predicted for the HRG precursor indicated that the higher mass 105-kDa form corresponds to the full-length HRG precursor (predicted size 100 kDa). The smaller (65 kDa) form likely represents that portion of the ligand that remains attached to the membrane after cleavage of the precursor to produce soluble HRG (45 kDa). This portion is probably internalized, which is supported by detection of the smaller form in the microsomal/lysosomal and microsomal fractions (Fig. 2, lanes 2 and 3) . Detection of a 98-kDa band in both the homogenate and cytoplasm, but not in the lysosomal and microsomal fractions, suggested this may be the underglycosylated HRG precursor contained in the endoplasmic reticulum. The smaller band detected in the homogenate and cytoplasm of both MDA-MB-231 and MCF-7 RV/H2 cells probably represents an artifact since MCF-7 cells do not produce HRG (35) .
Plasma Membranes Containing the HRG Precursor Activate p185
HER-2/neu Phosphorylation-Previous examination of the activity of a non-cleaved membrane-bound TGF-␣ mutant demonstrated that this ligand can stimulate EGF receptor (EGFR) phosphorylation in vitro (4, 5) . Using the Percoll-purified microsomal fraction (referred to as PM from now on) from the HRG-expressing cell line MDA-MB-231, similar experiments were performed to determine their ability to stimulate p185 HER-2/neu tyrosine kinase function. For this purpose, a p185 phosphorylation dose-response curve in MCF-7 cells was generated using increasing concentrations of a recombinantly produced 7-kDa rHRG-␤1, consisting of the EGF-like domain (Fig.  3A) . When two different concentrations of total PM protein were used to evaluate their effect on phosphorylation of the HER-2 receptor, the low dose (0.9 mg/ml) (Fig. 3A, last lane) of the PM fraction from MDA-MB-231 cells did not show stimulation. However, increasing to 2.25 mg/ml total MDA-MB-231 PM protein augmented p185
HER-2/neu phosphorylation to levels comparable with those seen with 0.032 nM of the free rHRG-␤1 (Fig. 3, A and B) . Quantitation of results of Western blot analyses (Fig. 3A) was conducted using densitometry scanning of the film (Fig. 3B) .
Plasma Membranes from the Heregulin-positive MDA-MB-231 Cells Compete with rHRG-␤1 for Binding to MCF-7
Cells-To further evaluate the specificity of the interaction between membrane-bound HRG and MCF-7 cells expressing all four RTK I receptors (34), displacement of binding of 125 Ilabeled rHRG-␤1 to MCF-7 cells was measured using increasing concentrations of unlabeled rHRG-␤1 and MDA-MB-231 purified plasma membranes. Two different doses of MDA-MB-231 PM vesicles were able to displace the binding of 125 IrHRG-␤1 to MCF-7 breast cancer cells (Fig. 4) . As a control, plasma membranes from the HRG-negative cell line MCF-7 RV/H2 were used in parallel in an attempt to compete the binding of 125 I-HRG-␤1 to MCF-7 cells. No evidence for displacement of HRG binding was found when a 0.17 mg/ml concentration of PM derived from MCF-7 cells was used, indicating that the displacement was not due to nonspecific membrane associated molecules. As an additional control, the same two concentrations of total protein (0.36 and 0.9 mg/ml) of the PM fraction from both MDA-MB-231 cells and MCF-7 RV/H2 cells were used to evaluate competitive binding of 125 I-labeled TGF-␣ to the EGFR-overexpressing cell line MDA-MB-468. Under the same conditions that binding of 125 I-labeled TGF-␣ was competed by increasing the concentrations of "cold" TGF-␣, no evidence for displacement of binding of the radiolabeled TGF-␣ was seen with either concentration of PM (data not shown). These data suggest the absence of other GFs that can bind to EGFR anchored to the plasma membranes of MDA-MB-231 cells and corroborates the specificity of the interaction of the MDA-MB-231 PM fraction with the HRG receptors expressed by MCF-7 parental cells. Finally, the possibility exists that free HRG might be released from the MDA-MB-231 plasma membrane anchored form by a protease produced in the cells during the incubation. This could result in phosphorylation of p185 HER-2/neu due to newly released soluble HRG in the culture medium, rather than a membrane-anchored ligand. To investigate the possible presence of soluble HRG in the incubation medium of MCF-7 parental cells after treatment with the MDA-MB-231 PM fractions, the conditioned medium was saved after treatment of cells with the plasma membrane fraction. Membranes containing the HRG precursor were pelleted by centrifugation at 105,000 ϫ g for 1 h, and the resultant supernatants were concentrated 30 (MCF-7 cell line), but not to cells overexpressing EGFR (MDA-MB-468), prompted a further evaluation of the nature and specificity of these interactions. To confirm the specificity of the differential activation (phosphorylation), Western blot analyses were performed after treatment of MCF-7 overexpressing HER-2 with PMs from the heregulin-producing (MDA-MB-231) and non-producing (MCF-7 RV/H2) cell lines. Immunoprecipitation of the different fractions was performed with an antip185 HER-2/neu antibody and detection using an anti-phosphotyrosine monoclonal antibody (Fig. 5 ). An increase in the level of phosphorylation of p185 HER-2/neu above the basal level (lane 1) was observed after treatment of the cells with a 1 nM amount of either the 7-kDa rHRG-␤1 fragment (lane 2) or full-length rHRG-␤1 (lane 3), indicating similar potency for the two recombinant forms of ligand in this assay. Two different antibodies were next used to study the specificity of induction of HER-2/ neu receptor phosphorylation by heregulin. Pre-incubation of full-length rHRG-␤1 with an anti-HRG polyclonal antibody (lane 4) blocked the stimulation of p185 HER-2/neu phosphorylation (compare with lanes 2 and 3). The identical result was obtained using an anti-HRG mouse monoclonal antibody (data not shown). When MCF-7/H2 cells were pre-incubated first with the anti-p185 HER-2/neu monoclonal antibody 2C4, which blocks heregulin binding to the receptor without inducing phosphorylation, and treated with the full-length rHRG-␤1, no augmentation in p185 HER-2/neu phosphorylation levels was observed (Fig. 5, lane 5) . The basal level of phosphorylation of the HER-2/neu receptor in MCF-7 cells treated with PM from MCF-7 RV/H2 cells in this assay is shown in lane 7 (Fig. 5A) . MCF-7 RV/H2 cells do not contain membrane-bound HRG as assessed by Northern blot and Taqman (34), as well as by immunohistochemistry, and absence of displacement of binding of 125 I-rHRG-␤1 to MCF-7 cells (this study). Incubation of the HER-2-overexpressing MCF-7 cells with 0.18 mg/ml MDA-MB-231 PM fraction increased p185 HER-2/neu phosphorylation to levels comparable to those obtained using full-length rHRG-␤1 at 1 nM (Fig. 5A lanes 8 and 3, respectively) . The same two antibodies used to block stimulation of p185 HER-2/neu phosphorylation by the full-length soluble ligand were then tested in combination with the PM fraction from HRG-expressing MDA-MB-231 cells. Pre-incubation of the MDA-MB-231 plasma membranes with the anti-HRG antibody (Fig. 5A, lane  9) or pre-incubation of the MCF-7 RV/H2 cells with 2C4 antireceptor antibody (Fig. 5A, lane 10) blocked the stimulation of p185 HER-2/neu phosphorylation produced by the PM fraction, indicating that this is a specific membrane-bound heregulin/HER-2-mediated phenomenon. As a control, the anti-p185 HER-2/neu monoclonal antibody 2H11, which does not block binding of fulllength heregulin to heterodimeric complexes containing p185 HER-2/neu or increase the phosphorylation level of the receptor, was used in an attempt to block the effects of the full-length soluble ligand as well as the membrane-anchored heregulin contained in the MDA-MB-231 PM. As expected, 2H11 failed to block the stimulation of receptor phosphorylation caused by either the membrane-bound or the soluble form of heregulin (Fig. 5A, lanes  11 and 6, respectively) . The results of the p185 HER-2/neu immunoprecipitation and Western blot analyses clearly indicate the presence of a heregulin-like activity associated with the plasma membranes of the HRG-producing cell line MDA-MB-231, which is not present in the plasma membranes of the HRG-negative MCF-7 RV/H2 cells. In addition, the data in Fig. 5 (Fig. 6, 2 and 1) . A greater stimulation of [ 3 H]thymidine incorporation, about 0.44 times higher than control levels (3), was observed when 0.04 mg/ml total protein from the membrane-anchored heregulin-containing MDA-MB-231 PM fraction was added to the cells (Fig. 6, 4) .
Membrane-anchored HRG-expressing Cells and RTK I-containing Cells
Physically Interact-To study the possible physical interaction between cells expressing membrane-anchored heregulin and cells expressing HRG receptors, MDA-MB-231 cells and MCF-7 cells overexpressing HER-2/neu were co-cultured in a 1 to 1 ratio. These studies demonstrated that HRGexpressing cells physically interact with MCF-7 RV/H2 cells (Fig. 7A) . The specificity of this interaction is further supported by blockage of this phenomenon by pre-incubation of MCF-7 cells with full-length rHRG (Fig. 7B) or the anti-HER-2/neu antibody 2C4 (Fig. 7C) . As expected, the 2H11 anti-receptor antibody, which does not block HRG binding to HER-2/neu complexes, does not result in blockage of cell-cell interactions (Fig. 7D) . These data indicate a specific interaction between plasma membrane-bound HRG and cells expressing the HER/ neu receptor on their surface. An elevated level of the main HRG receptor, HER-3, in MCF-7 cells overexpressing HER-2 (34) probably facilitates the cell-cell interaction shown. The blockade of this interaction (Fig. 7) and receptor activation (Fig. 5) by the anti-HER-2 antibody 2C4 is probably a consequence of the reduction in affinity that heterodimeric complexes containing the HER-2 receptor undergo when HER-2 binds 2C4. These data support previous reports demonstrating the important role of HER-2 in the HRG binding receptor heterodimer (22, 40) . DISCUSSION The heregulins are members of a family product of the differential splicing of three genes (8, 11, 10, 41) . The amino acid sequence analysis of the products of the human heregulin gene predicts the synthesis of HRG-␣ and HRGs-␤1/␤2 isoforms as transmembrane precursors (8) . Similarly, analysis of the NDF sequence predicted its synthesis as a membrane-bound protein, which is further processed by protease cleavage, releasing a soluble 44-kDa ligand (9) . Two other peptide growth factors that are synthesized as membrane-anchored precursors, namely CSF-1 and KL, are products of differentially spliced genes (2) . It has been demonstrated that the short forms of CSF-1 (42) and the KL-2 isoform of the c-Kit ligand (43) are found on the surface of producing cells.
Given the high degree of homology between the various members of the HRG/NDF family (8, 41), the possibility of several membrane-bound forms of heregulin on the surface of MDA-MB-231 cells exists. The results of both the immunocytochemical analyses and Western blot data in the current study clearly demonstrate the presence of membrane-anchored heregulin on the surface of the HRG-producing human breast cancer cell line MDA-MB-231. The size of the HRG identified in the cell lysates from MDA-MB-231 cells by Western blotting is close to the size predicted for the fully glycosylated HRG-␣ precursor. In addition, we detected higher M r bands (data not shown) using antibodies raised against the precursor for HRG-␤1 (645 amino acids). The high homology between the different HRG isoforms raises the question about the identity of the HRG molecule(s) preferentially bound to the plasma membranes of MDA-MB-231 cells used in the current study, since these are known to produce both ␣ and ␤ splice variants (8) . One way to identify the form(s) of heregulin present on the plasma membrane of MDA-MB-231 cells could be using spectroscopic approaches. Additionally, future availability of monospecific antibodies able to discriminate between these closely related isoforms of HRG will also help on the identification of the form of the ligand that is preferentially bound to the plasma membranes of HRG-producing cells.
Use of highly purified plasma membranes from the HRGpositive cell line MDA-MB-231 demonstrate that they stimu- (27) analyzed the activity of membrane-bound forms of SMDF transfected into Chinese hamster ovary cells on HER-3 expressed by Schwann cells. In the present study, however, breast cancer cells nonengineered to express HRG were analyzed. This report is also unique in that there are no previous studies on the activation of HER-2 by membrane-bound forms of HRG, or on the juxtacrine interaction between cells expressing HRG and breast cells expressing its receptors.
Although EGFR activation by non-cleavable TGF-␣ mutants has been readily established (4, 5) , demonstration of juxtacrine interactions is frequently more difficult due to the fact that most membrane-anchored growth factors can be converted to soluble forms with similar activity (44) . The absence of soluble HRG in the conditioned media tested in the current studies makes the membrane-bound form of HRG present on the surface of MDA-MB-231 cells the likely candidate for this activity. The membrane-anchored forms of KL, TNF, and boss are examples of other membrane-bound peptide growth factors (2) . These growth factors are believed to conduct their biologic function while bound to the surface of expressing cells and are specifically produced as transmembrane ligands, which remain anchored to the cell surface (44) . Another possibility could be that the release of 45 kDa HRG is a tightly regulated process. Therefore, heregulin could perform a different role as a membrane-anchored ligand while processing and release of the free form occurs when it is needed for a specific functions.
The presence of immobilized forms of growth factors on the cell surface indicates cell-cell communication, as well as cellcell adhesive interactions. The mechanisms by which release of cleavable forms of membrane-bound GFs from their precursors on the plasma membrane occur are poorly understood. Membrane-anchored growth factor precursors may accumulate on the cell surface due to limitations in the proteolytic process that converts them into soluble factors (2) . A putative trypsin-like proteolysis site (Lys-Arg) in the stalk connecting the EGF-like domain and the transmembrane domain is shared by all transmembrane forms of HRG/NDF (41) . The identity of the proteases responsible for the release of soluble heregulin from its membrane-anchored precursor and how is this process regulated are still obscure. Shedding of transmembrane neuregulin by the TNF-␣-converting enzyme has recently been reported (45) . Studies of the mechanisms by which cleavage of transmembrane HRG takes place, releasing the soluble ligand, and knowledge of their control may be important in understanding the biology of the heregulin receptor system.
Confirmation of the identity of the activator of p185 HER-2/neu phosphorylation as membrane-bound heregulin was achieved by using both anti-HRG, and anti-receptor antibodies to block the increase in phosphorylation of the HER-2/neu product observed after incubation of MCF-7 RV/H2 cells with rHRG-␤1 or with the MDA-MB-231 PM. The results from this immunoprecipitation and Western blot analysis, together with the data obtained from the competitive displacement of binding, are rather important because they demonstrate conclusively the specific activation of p185 HER-2/neu phosphorylation by membrane-bound heregulin. Direct binding of the membrane-anchored HRG to p185 HER-2/neu -containing heteromers is suggested by blockade of the effects of both full-length rHRG-␤1 and the MDA-MB-231 PM, on receptor phosphorylation by pre-incubation of the MCF-7 cells with the anti-receptor antibody 2C4. Heregulin has also been shown to stimulate the phosphorylation of p180 HER-3 (21) and p180 HER-4 (19) . However, receptor transphosphorylation by association of EGFR-HER-2 (46), HER-2-HER-3 (22) , and HER-2-HER-4 (19) as heterodimers has been established as a mechanism for heregulin activation of phosphorylation of this family of RTKs.
The capacity of membrane-anchored heregulin to produce effects downstream to receptor phosphorylation in cells over- expressing HER-2/neu was also demonstrated. Induction of [ 3 H]thymidine incorporation by MDA-MB-231 PM in MCF-7 RV/H2 cells, as well as in the breast cancer cell lines SK-BR-3 and BT-20 RV/H2 (not shown here), was comparable or even higher to than the levels obtained by using a soluble form of HRG. Two possible interpretations for a higher activity of the PM fraction on induction of [ 3 H]thymidine incorporation include: (a) the presence of other membrane-bound molecule(s) that bind to a GF receptor, i.e. EGFR, and could act synergistically with membrane-anchored HRG; or (b) the possibility that the higher incorporation of thymidine in cells treated with MB-HRG is due to amphiregulin stimulation of EGFR, since MCF-7 cells have been reported to produce this ligand (47) . The likelihood of this is decreased by the absence of significant displacement of binding of TGF-␣ to the EGFR-overexpressing MDA-MB-468 cells by the PM from either MCF-7 or MDA-MB-231 cells. These data suggest that MB-HRG is more potent than soluble HRG in stimulating thymidine incorporation in HER-2-overexpressing cells. The explanation for this difference could be that membrane-bound HRG induces a more persistent signal by sustained activation of HER-2-containing heterocomplexes. Previously published data show that HER-2 is clustered and internalized via coated pits (48) , and this is similar to the mechanism used by the boss-sevenless system, which also demonstrates receptor clustering into coated pits after ligand binding (6) . The membrane-bound ligand-receptor complex cluster containing several receptor molecules is internalized at a slower rate compared with the rate for a free ligand-receptor complex (6) . Moreover, members of the RTK I family, except EGFR, are endocytosis-impaired (49) . Binding of MB-HRG to HER-2-containing receptor heterocomplexes and subsequent internalization could be further slowed, increasing the signaling of the membrane-bound ligand-receptor complex in HER-2-expressing cells.
Two other membrane-anchored activators for p185
HER-2/neu expressed in both normal and malignant tissues have been reported (50) . These two transmembrane ligands, ASGP-1 and ASGP-2, share no homology with heregulin and consist of heterodimers of the mucin family. Whether these or other activators of the HER-2/neu receptor participate in p185 activation is still under study. A number of membrane-anchored growth factors play a role in ligand-receptor juxtacrine interactions (44) . In the current study, we demonstrate juxtacrine interactions between HRGproducing cells and HER-2/neu-expressing cell lines. The results further support cell-cell communication mediated by this receptor-MB ligand complex might occur in vivo. Moreover, the specific interaction between MDA-MB-231 cells bearing membrane-bound HRG and MCF-7 cells overexpressing HER-2 was also demonstrated.
Several membrane-anchored growth factors from invertebrates play a role in determination of cell fate of various epithelial and neuronal cells. Examples of these are the bride of sevenless (boss), as well as other membrane proteins in Drosophila and Caenorhabditis elegans (44) . The presence of a large cytoplasmic domain in the HRG transmembrane forms is unique among the EGF-like peptides (2, 41) . It has been suggested that the membrane-anchored HRG could signal downstream through its cytoplasmic tail, acting as a receptor as well (28) . This precedent was demonstrated in studies in which membrane-anchored heparin-binding epidermal growth factor, another member of the EGF family, was identified as the receptor for Diphtheria toxin (51) .
The HER-2/neu proto-oncogene is widely expressed in normal tissues during development, especially in the nervous system (52) . Heregulin expression is also high in tissues of the nervous system (53) . This coincidental high expression of both ligand and receptor in neuronal tissues, as well as the identification of glial growth factors, ARIA and SMDF as HRG homologs, strongly indicate a possible role for heregulin as a neurotrophin. Additionally, membrane-anchored heregulin could play an as yet undetermined role in cell-cell contact, cell adhesion, or even cell survival, which are important processes in the development of normal tissues, as well as in malignant progression. The expression of HRG in a panel of breast and ovarian epithelial cells has been quantitated by Taqman (34) . Normal breast (HMEC) as well as immortalized cells (HBL-100) express higher levels of HRG than those in breast cancer MDA-MB-231 cells. In addition, ovarian cancer cells 2008 and C13 produce HRG. We have also detected MB-HRG on the surface of HBL-100 cells by immunocytochemistry (data not shown). Together, these data support the existence of a juxtacrine mechanism involving HER⅐HRG complexes in vivo. As demonstrated in this study, membrane-bound HRG is present in malignant breast cells and is active on cells that express HER-2/neu. The results presented suggest a possible function for this receptor-membrane-bound ligand system in vivo.
